Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Editorial: Hormone resistance in cancer.
Phoenix JT, Budreika A, Kostlan RJ, Hwang JH, Fanning SW, Kregel S. Phoenix JT, et al. Among authors: fanning sw. Front Endocrinol (Lausanne). 2023 Aug 24;14:1272932. doi: 10.3389/fendo.2023.1272932. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37693345 Free PMC article. No abstract available.
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. Fanning SW, et al. Elife. 2018 Nov 29;7:e37161. doi: 10.7554/eLife.37161. Elife. 2018. PMID: 30489256 Free PMC article.
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.
Abderrahman B, Maximov PY, Curpan RF, Fanning SW, Hanspal JS, Fan P, Foulds CE, Chen Y, Malovannaya A, Jain A, Xiong R, Greene GL, Tonetti DA, Thatcher GRJ, Jordan VC. Abderrahman B, et al. Among authors: fanning sw. Mol Cancer Ther. 2021 Jan;20(1):11-25. doi: 10.1158/1535-7163.MCT-20-0563. Epub 2020 Nov 11. Mol Cancer Ther. 2021. PMID: 33177154 Free PMC article.
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells.
Hosfield DJ, Weber S, Li NS, Sauvage M, Joiner CF, Hancock GR, Sullivan EA, Ndukwe E, Han R, Cush S, Lainé M, Mader SC, Greene GL, Fanning SW. Hosfield DJ, et al. Among authors: fanning sw. Elife. 2022 May 16;11:e72512. doi: 10.7554/eLife.72512. Elife. 2022. PMID: 35575456 Free PMC article.
ESR1 activating mutations: From structure to clinical application.
Grinshpun A, Chen V, Sandusky ZM, Fanning SW, Jeselsohn R. Grinshpun A, et al. Among authors: fanning sw. Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188830. doi: 10.1016/j.bbcan.2022.188830. Epub 2022 Nov 4. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36336145 Free article. Review.
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL. Fanning SW, et al. Elife. 2016 Feb 2;5:e12792. doi: 10.7554/eLife.12792. Elife. 2016. PMID: 26836308 Free PMC article.
30 results